AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2014
Oct 15, 2014
31071_dirs_2014-10-15_eec85503-5c1b-4aba-82a9-1f1a0c15c53a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2014-10-15
Reporting Person: Anzalone Christopher Richard (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-10-15 | Common Stock | P | 16000 | $6.32 | Acquired | 260173 | Direct |
Footnotes
F1: Represents the weighted average price at which shares were sold within a range between $6.02 and $6.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.